1   Cardiorespiratory fitness, polygenic risk, and breast cancer in postmenopausal women:

2   a prospective cohort study

Kumpei Tanisawa[1*], Daiki Watanabe[2], Qian Li[3], Xiayue Fan[3], Xiaomin Sun[4*]

[1]Faculty of Sport Sciences, Waseda University, Tokorozawa, Saitama 359-1192, Japan

[2]National Institute of Biomedical Innovation, National Institutes of Biomedical Innovation,

Health and Nutrition, Ibaraki-city, Osaka, Japan.

[3]Med-X Institute, Center for Immunological and Metabolic Diseases, the First Affiliated

Hospital of Xi'an JiaoTong University, Xi'an JiaoTong University, Xi'an, Shaanxi 710049,

China.

[4]Global Health Institute, School of Public Health, Xi'an JiaoTong University Health Science

Center, Xi'an, Shaanxi 710061, China

*Correspondence to: Kumpei Tanisawa, Ph.D

Faculty of Sport Sciences, Waseda University

2-579-15 Mikajima, Tokorozawa, Saitama 359-1192, Japan

TEL/FAX: +81-4-2947-6745

E-mail: tanisawa@waseda.jp

*Correspondence to: Xiaomin Sun, Ph.D

Global Health Institute, School of Public Health, Xi'an Jiaotong University Health Science

Center, Xi'an 710061, China

E-mail: gzhtxiaomin@163.com

Abstract

Objective: To examine the joint associations of cardiorespiratory fitness (CRF) and polygenic risk with incident breast cancer and whether higher CRF attenuates excess breast cancer risk associated with high polygenic risk in postmenopausal women.

Methods: This prospective cohort study included postmenopausal women from the UK Biobank. CRF was estimated using a submaximal cycle ergometer test, and genetic susceptibility was assessed using a breast cancer polygenic risk score (PRS). Associations of CRF and PRS with incident breast cancer were examined using Cox proportional hazards models with age as the underlying time scale. Analyses were conducted overall and stratified by age (40–59 and ≥60 years) and body mass index (BMI) (<25 and ≥25 kg/m^2). Multiplicative and additive interactions were evaluated, with additive interaction assessed using the relative excess risk due to interaction (RERI).

Results: During a median follow-up of 10.7 years, 500 incident breast cancer cases were identified among 13,907 postmenopausal women. Higher CRF was associated with a lower breast cancer risk in a dose–response manner. Although multiplicative interaction was not significant, higher CRF attenuated excess risk associated with high polygenic risk on the additive scale (RERI −0.84, 95% CI −1.56 to −0.12). This attenuation was particularly evident among women aged ≥60 years and those with BMI ≥25 kg/m^2.

Conclusion: Higher CRF was associated with a lower breast cancer risk and attenuated excess breast cancer risk associated with high polygenic risk, particularly among postmenopausal women at elevated baseline risk, supporting a potential role for improving CRF in genetically informed breast cancer prevention.

Summary Box

What is already known on this topic

• Higher cardiorespiratory fitness (CRF) is associated with a lower risk of breast cancer.

• Polygenic risk scores identify women at elevated inherited risk of breast cancer.

• It remains unclear whether higher CRF can mitigate the impact of genetic susceptibility

on breast cancer risk.

What this study adds

• Higher CRF was associated with lower breast cancer incidence in postmenopausal

women.

• Higher CRF attenuated excess breast cancer risk associated with high polygenic risk on

the additive scale.

• This attenuation was particularly evident among women aged ≥60 years and those with

overweight or obesity.

How this study might affect research, practice or policy

• Improving CRF may help reduce breast cancer risk among postmenopausal women at

elevated genetic risk.

• CRF assessment may support risk stratification and personalised prevention strategies.

• Promoting fitness-enhancing behaviours may complement genetic risk assessment in

breast cancer prevention.

Introduction

Cardiorespiratory fitness (CRF) is an objective physiological measure reflecting the integrated capacity of the cardiovascular and respiratory systems and habitual levels of physical activity[1]. Higher levels of CRF have been consistently associated with reduced risks of various chronic diseases[2] and mortality[2,3]. Prospective cohort studies suggest an inverse association between CRF and breast cancer incidence[4,5], supporting a potential role for improving CRF in breast cancer prevention.

Genetic susceptibility also plays a substantial role in breast cancer development. Although high-penetrance hereditary breast cancer syndromes account for only a small proportion of cases[6], most inherited susceptibility to breast cancer is polygenic, reflecting the cumulative contribution of numerous common variants[7,8]. Genome-wide association studies (GWASs) have identified numerous loci associated with breast cancer risk[9,10], and polygenic risk scores (PRS) derived from GWAS data enable stratification of breast cancer risk across the general population[7,8].

An important clinical and public health question is whether modifiable factors such as CRF attenuate excess breast cancer risk associated with high genetic susceptibility. A previous study has suggested that favourable lifestyle behaviours, including higher levels of physical activity, may attenuate the impact of genetic susceptibility on breast cancer risk[11]. Given that CRF is an objective marker of habitual physical activity, this observation raises the possibility that CRF may also be particularly relevant among women with higher genetic susceptibility. However, whether CRF modifies the association between polygenic risk and breast cancer remains unclear.

Therefore, the present study aimed to examine the joint association of CRF and PRS with

incident breast cancer in postmenopausal women from the UK Biobank. We evaluated

interactions between CRF and PRS and additionally assessed dose–response patterns of CRF

and PRS, as well as heterogeneity by baseline risk.

Methods

Study Population

The UK Biobank is a large prospective cohort study that recruited over 500,000 participants

aged 40–69 years between 2006 and 2010 across the United Kingdom[12]. At baseline,

participants completed detailed questionnaires, underwent standardized physical

examinations, and provided biological samples.

For the present analysis, we included postmenopausal women with available CRF and breast

cancer PRS data. Premenopausal women were excluded because of the difference in breast

cancer etiology. Postmenopausal status was defined as natural menopause or menopause

resulting from bilateral oophorectomy. Participants were excluded if they were men

(n=228,973); lacked estimated maximal oxygen uptake (VO₂max) data (n=238,082); were

premenopausal at baseline (n=12,198); had a history of hysterectomy (n=2,184); had a

history of any cancer at baseline (n=2,294); were of non-European ancestry (n=4,297, based

on UK Biobank field: 22,006); had missing PRS data (n=58); or had extreme VO₂max

values (≥3 standard deviations from the mean, n=135). The final analytical sample comprised

13,907 postmenopausal women (Figure 1).

Assessment of CRF

CRF was assessed by estimating VO₂max (mL·kg⁻¹·min⁻¹) using a validated submaximal

cycle ergometer test administered at baseline. VO□max was derived from heart-rate

responses during graded submaximal exercise, incorporating age, sex, body mass, and

workload, according to the UK Biobank protocol[13]. This procedure has been validated

against directly measured VO_2max[14]. To account for age-related differences in CRF,

participants were categorised into age-specific quartiles of VO□max within predefined age

groups (40–49 years, 50–59 years, and ≥60 years) for categorical analyses. Age-specific

quartile cut-points for CRF are provided in Supplementary Table 1.

PRS for Breast Cancer

Genetic susceptibility to breast cancer was assessed using the standard PRS for breast cancer,

previously generated from external GWAS data and available in the UK Biobank (field:

26,220)[15]. The PRS for each participant was calculated as the genome-wide sum of

per-variant posterior effect sizes weighted by allele dosage and was then standardized to have

a mean of zero and a standard deviation of one. Participants were categorised into quartiles of

the PRS for categorical analyses. Quartile cut-points for PRS are provided in Supplementary

Table 1.

Ascertainment of Breast Cancer

Incident breast cancer cases were ascertained through linkage to national cancer registries of

England, Scotland, and Wales and defined as the first primary diagnosis of breast cancer

occurring after the date of baseline assessment, identified using International Classification of

Diseases, 10th Revision (ICD-10) codes C50. Participants were followed from the date of

baseline assessment until breast cancer diagnosis, death, loss to follow-up, or December 31,

2020, whichever occurred first. As a secondary outcome, breast cancer–specific mortality was

defined as death with breast cancer (ICD-10 code C50) recorded as the underlying cause,

using the same ascertainment procedures described above.

Covariates

Covariates were selected a priori based on established breast cancer risk factors. These

included family history of breast cancer (yes, no), socioeconomic status assessed using the

Townsend deprivation index (quintile), alcohol consumption frequency (<3 times a month,

1–4 times a week, daily or almost daily), smoking status (never, former, current), ever use of

hormone replacement therapy (yes, no), age at menarche (<12, 12–13, ≥14 years), number of

live births (0, 1, 2, ≥3 live births), and age at first birth (<25, 25–29, ≥30 years). Family

history of breast cancer was defined using self-reported maternal and sibling history. Body fat

percentage (continuous) was considered an adiposity-related covariate, which was included in

fully adjusted models. All covariates were defined using measurements and questionnaire

responses collected at baseline.

Statistical Analysis

All analyses were conducted using R (version 4.5.1), with statistical significance set at $p <$

0.05. Missing covariate data were handled using multiple imputation by chained equations

(20 datasets) under the missing-at-random assumption. The proportion of missing data for

each covariate is shown in Supplementary Table 2. Imputation was applied only to covariates

with missing data; primary exposures (CRF and PRS) and the outcome were not imputed.

The imputation model included all covariates and the event indicator. Models were fitted

separately within each imputed dataset, and estimates from each dataset were pooled using

Rubin's rules. Associations of CRF and PRS with incident breast cancer and breast

cancer–specific mortality were examined using Cox proportional hazards models with age as

the underlying time scale. The proportional hazards assumption was evaluated using

Schoenfeld residuals, and no meaningful violations were observed. Model 1 was adjusted for

established breast cancer risk factors (family history of breast cancer, Townsend deprivation

index, alcohol consumption frequency, smoking status, hormone replacement therapy use,

age at menarche, number of live births, and age at first birth). Because CRF is closely related

to adiposity, Model 2 was further adjusted for body fat percentage to examine whether the

association was independent of adiposity. When PRS was the primary exposure, the crude

model and Model 1 were applied. Hazard ratios (HRs) and 95% confidence intervals (CIs)

were estimated across quartiles of CRF and PRS using the lowest quartile as the reference.

Linear trends were assessed using Wald tests with CRF and PRS modelled as continuous

variables. Analyses were conducted in the overall sample and stratified by age (40–59 years

and ≥60 years), body mass index (BMI) (<25 kg/m^2, $≥25$ kg/m^2), with BMI ≥25 kg/m²

defined as overweight or obesity, and PRS categories. Nelson–Aalen cumulative hazard

curves were constructed to visualise the cumulative incidence of breast cancer across CRF

and PRS categories. Restricted cubic spline regression was used to examine potential

non-linear associations of CRF and PRS with breast cancer risk. Joint associations of CRF

and PRS were examined by cross-classifying participants into dichotomised categories

(Q1–Q3 vs Q4) and fitting Cox models with the joint category of low-to-moderate PRS

(Q1–Q3) and low-to-moderate CRF (Q1–Q3) as the reference group. Multiplicative

interaction between CRF and PRS categories was evaluated by including cross-product terms,

with statistical significance assessed using likelihood-ratio tests. Additive interaction between

CRF and PRS categories was evaluated using the relative excess risk due to interaction

(RERI), with 95% confidence intervals derived using the delta method and pooled across

imputations. Sensitivity analyses excluded breast cancer cases diagnosed within the first year

of follow-up to reduce the potential for reverse causation.

Results

Participant Characteristics

During a median follow-up of 10.7 years (IQR 10.6–10.8), 500 incident breast cancer cases were identified among 13,907 postmenopausal women. Table 1 presents the baseline characteristics of the study population according to quartiles of CRF before multiple imputation. Women in higher CRF quartiles had lower body fat percentage and more favorable lifestyle profiles compared to those in lower CRF quartiles.

Association between PRS and Breast Cancer Incidence

The association between PRS and incident breast cancer is shown in Supplementary Table 3. After adjustment for covariates (Model 1), PRS was positively and progressively associated with incident breast cancer (p for trend < 0.001). Restricted cubic spline analyses further demonstrated an approximately linear dose–response relationship between PRS and breast cancer risk (p for nonlinearity = 0.160, Supplementary Figure 1). Nelson–Aalen curves were consistent with the Cox regression results, showing progressively greater cumulative risk across higher PRS quartiles (Figure 2A). Age-stratified analysis showed that the association between PRS and incident breast cancer was stronger in women aged ≥60 years than in those aged 40–59 years (Supplementary Table 3 and Supplementary Figure 2). In secondary analyses of breast cancer–specific mortality, PRS was also positively and progressively associated with incident breast cancer (Supplementary Table 4).

Association between CRF and Breast Cancer Incidence

The association between CRF quartiles and incident breast cancer is shown in Table 2. In Model 1, CRF was inversely associated with incident breast cancer (p for trend = 0.001). Further adjustment for body fat percentage in Model 2 did not substantially change the results

(p for trend = 0.013). Restricted cubic spline analyses were consistent with these findings and

supported an approximately linear inverse dose–response relationship between CRF and

breast cancer risk (p for nonlinearity = 0.494, Supplementary Figure 3). Cumulative hazard

curves were consistent with the Cox regression results, showing lower cumulative risk across

higher CRF quartiles (Figure 2B). Similar dose–response patterns were observed in age- and

BMI-stratified analyses (Supplementary Table 5, Supplementary Figure 4 and 5); however, a

significant linear association was observed only in women aged ≥60 years (p for trend =

0.014) and those with BMI ≥25 kg/m^2 (p for trend = 0.006), but not in those aged 40–59

years (p for trend = 0.459) and those with BMI <25 kg/m^2 (p for trend = 0.527). In the

sensitivity analysis excluding breast cancer cases diagnosed within the first year of follow-up,

the overall pattern of associations remained consistent (Supplementary Tables 6 and 7),

indicating minimal influence of reverse causation. The association between CRF and breast

cancer-specific mortality was not statistically significant (Supplementary Table 8).

Association between CRF and Breast Cancer Incidence Across PRS Quartiles

We next examined the association between CRF and breast cancer risk stratified by PRS

quartiles (Table 2, Supplementary Figure 6). Higher CRF was significantly associated with a

lower breast cancer risk among women in the highest PRS quartile (p for trend = 0.001 in

Model 2), whereas no significant association was observed in the low-to-moderate PRS

(Q1–Q3) quartiles (p for trend > 0.05). Restricted cubic spline analyses of CRF within PRS

categories indicated that the inverse linear dose–response relationship between CRF and

breast cancer risk was largely confined to women with high polygenic risk (Supplementary

Figure 6).

Joint Associations and Interaction of CRF and PRS with Breast Cancer Incidence

Joint associations of CRF and PRS quartiles with incident breast cancer are shown in Figure

3 and Supplementary Table 9. Women with high PRS (Q4) and low-to-moderate CRF

(Q1–Q3) exhibited the highest risk of breast cancer in the overall sample (HR 2.58, 95% CI

2.12 to 3.14, p < 0.001 in Model 2). Although no significant multiplicative interaction

between CRF and PRS was detected (HR 0.72, 95% CI 0.46 to 1.15, p=0.168), additive

interaction analyses demonstrated a significant negative RERI in the overall sample (RERI

−0.84, 95% CI −1.56 to −0.12, p=0.022). In age-stratified analyses, this additive interaction

was particularly pronounced among women aged ≥60 years (RERI −1.10, 95% CI −1.93 to

−0.27, p=0.009), whereas no significant interaction was observed among women aged 40–59

years (RERI −0.18, 95% CI −1.59 to 1.22, p=0.797). In this older age group, women with

high PRS and high CRF did not show a statistically significant increase in breast cancer risk

compared with the reference group (HR 1.29, 95% CI 0.81 to 2.06, p=0.285). Similar patterns

were observed in BMI-stratified analyses. A significant additive interaction was detected

among women with BMI ≥25 kg/m^2 (RERI −1.23, 95% CI −2.17 to −0.29, p=0.010), whereas

no significant interaction was observed among those with BMI <25 kg/m^2 (RERI −0.97, 95%

CI −2.32 to 0.37, p=0.157). Among women with overweight or obesity, those with high PRS

and high CRF did not show an increased risk compared with the reference group (HR 0.85,

95% CI 0.38 to 1.94, p=0.707). In the sensitivity analysis excluding breast cancer cases

diagnosed within the first year of follow-up, the overall pattern of associations remained

consistent (Supplementary Table 10). Cumulative hazard curves according to joint CRF and

PRS categories further supported these findings. Among women with high PRS, the

cumulative hazard curves were largely overlapping between CRF groups before age 65 years

but began to diverge thereafter, with higher CRF associated with a slower accumulation of

breast cancer risk (Figure 2C).

Discussion

In this prospective cohort study of postmenopausal women from the UK Biobank, higher CRF was inversely associated with a lower breast cancer risk. Women with high PRS had elevated risk, and higher CRF was associated with attenuation of excess genetic risk on the additive scale, and the effect was greater among those aged ≥60 years and those with overweight or obesity. In contrast, attenuation of excess risk was not evident among women aged 40–59 years and those with BMI <25 kg/m^2. No clear association was observed for breast cancer–specific mortality. Overall, these findings suggest that higher CRF attenuates excess breast cancer risk associated with genetic susceptibility in postmenopausal women, particularly among those at elevated baseline risk.

Comparison with Previous Studies

In the present study, higher CRF was associated with a lower risk of breast cancer overall, consistent with previous prospective evidence[5]. In BMI-stratified analyses, the inverse association between CRF and breast cancer risk was observed among women with overweight or obesity but not in those with BMI <25 kg/m². A prospective analysis of UK Biobank similarly reported that higher CRF was associated with a lower breast cancer risk primarily among women with overweight or obesity[4]. We also observed that the inverse association between CRF and breast cancer risk was most evident among women in the highest PRS quartile and those aged ≥60 years. These findings suggest that CRF plays a particularly important role among women at elevated baseline risk, as well as those with higher genetic susceptibility.

In addition, we observed that higher CRF attenuated excess breast cancer risk associated with high PRS. To our knowledge, no previous prospective studies have investigated the joint

associations and potential interaction between objectively assessed CRF and genetic

susceptibility in relation to incident breast cancer. The present findings therefore extend

existing evidence by indicating that higher CRF may influence the phenotypic manifestation

of genetic risk.

Biological Interpretation

The finding that higher CRF attenuated excess breast cancer risk associated with genetic

susceptibility among women aged ≥60 years is biologically plausible. Ageing is accompanied

by immune senescence[16], hormonal changes including increased peripheral production in

adipose tissue[17], and accumulated cellular damage[18], which may amplify the phenotypic

manifestation of genetic risk. Together, these processes may create a protumorigenic

environment. Higher CRF is associated with improved metabolic regulation[19], reduced

systemic inflammation[20], and enhanced immune surveillance[21], which may help limit

tumor development. Among women aged ≥60 years, where genetic susceptibility may be

more strongly expressed with advancing age, physiological resilience indexed by CRF may

therefore exert a more apparent influence. Notably, the attenuation of excess risk associated

with high polygenic risk was also confined to women with BMI ≥25 kg/m². Because

adiposity contributes to metabolic dysregulation[22], chronic inflammation[22], and

increased local estrogen production[23], the protective influence of CRF may be particularly

evident in individuals with greater metabolic vulnerability. Together, these findings suggest

that higher CRF may mitigate the impact of genetic susceptibility on breast cancer risk

primarily in biologically susceptible groups, such as older women and those with overweight

or obesity.

The absence of clear attenuation among women aged 40–59 years warrants cautious

interpretation. Breast cancer etiology in relatively younger postmenopausal women may be

more strongly shaped by life-course reproductive factors[24] and cumulative hormonal

exposures established earlier in life[25], potentially diminishing the relative contribution of

CRF.

Clinical and Translational Implications

The growing use of PRS in breast cancer risk stratification enables the identification of

individuals at elevated genetic risk[7], underscoring the importance of modifiable factors that

may reduce disease risk. Our findings suggest that higher CRF may attenuate excess breast

cancer risk associated with elevated genetic susceptibility in postmenopausal women at

elevated baseline risk, supporting the promotion of fitness-enhancing behaviours as a

practical prevention strategy alongside genetic risk assessment. In contrast, attenuation of

excess risk by higher CRF was not evident among women aged 40–59 years and those with

BMI <25 kg/m², suggesting that additional preventive strategies may be needed for these

groups.

Strengths and Limitations

This study has several strengths. The prospective design and adequate sample size enabled

robust assessment of incident breast cancer. CRF was estimated using an objective

submaximal exercise test, providing a more reliable physiological measure than self-reported

physical activity. The use of a PRS allowed evaluation of genetic susceptibility, and the

assessment of additive interaction offers clinically and public health–relevant insight into risk

modification. In addition, age- and BMI-stratified analyses enhanced the biological and

clinical interpretation of the findings.

Several limitations should be considered when interpreting these findings. First, CRF was

assessed only at baseline, and changes over time were not captured, potentially limiting

assessment of long-term exposure effects. Second, the analytic sample was restricted to

women of European ancestry, which may limit generalizability to other populations. Third,

residual confounding may remain despite adjustment for established breast cancer risk factors.

Fourth, in age-stratified analyses, particularly among women aged 40–59 years and those

with BMI <25 kg/m², the number of incident cases was modest, which may have reduced

statistical power to detect additive interaction and contributed to uncertainty regarding age-

and BMI-specific heterogeneity. Finally, as an observational study, causal inference cannot be

established, and the findings require replication in independent cohorts.

Conclusion

In this prospective cohort of postmenopausal women, higher CRF was associated with a

lower breast cancer risk and attenuated excess breast cancer risk associated with high

polygenic risk, particularly among postmenopausal women aged ≥60 years and those with

overweight or obesity. These findings suggest that high CRF may mitigate the impact of

genetic susceptibility on breast cancer risk in postmenopausal women at elevated baseline

risk and highlight a potential role for improving CRF levels within genetically informed

prevention strategies.

Acknowledgements

This research was conducted using the UK Biobank Resource under application number

185057. The authors thank the UK Biobank participants and staff for their valuable

contributions.

Author contributions

KT conceived the study. KT conducted the analyses and drafted the manuscript. All authors contributed to interpretation of the data, critically revised the manuscript, and approved the final version.

Funding

This study was financially supported by the National Natural Science Foundation of China (No. 32371228), the Key Research and Development Program of Shaanxi Province (No. 2025SF-YBXM-367), Fundamental Research Funds of Xi'an Jiaotong University (xtr052023011).

Competing interests

The authors declare that they have no competing interests

Patient and public involvement

Patients and the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Patient consent for publication

Not required.

Ethics approval

UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (REC reference: 11/NW/0382). All participants provided written informed consent.

Data availability statement

395 Data are available from the UK Biobank upon application (www.ukbiobank.ac.uk), subject to

396 approval.

References

Ross R, Blair SN, Arena R, *et al.* Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement from the American Heart Association. *Circulation*. 2016;134:e653–99. doi: 10.1161/CIR.0000000000000461

Lang JJ, Prince SA, Merucci K, *et al.* Cardiorespiratory fitness is a strong and consistent predictor of morbidity and mortality among adults: an overview of meta-analyses representing over 20.9 million observations from 199 unique cohort studies. *Br J Sports Med*. 2024;58:556–66. doi: 10.1136/bjsports-2023-107849

Kodama S, Saito K, Tanaka S, *et al.* Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and Women A Meta-analysis. *JAMA*. 2009;301(19):2024–35. doi: 10.1001/jama.2009.681

Christensen RAG, Knight JA, Sutradhar R, *et al.* Association between estimated cardiorespiratory fitness and breast cancer: A prospective cohort study. *Br J Sports Med*. 2023;57:1238–47. doi: 10.1136/bjsports-2021-104870

Katsaroli I, Sidossis L, Katsagoni C, *et al.* The Association between Cardiorespiratory Fitness and the Risk of Breast Cancer in Women. *Med Sci Sports Exerc*. 2024;56:1134–9. doi: 10.1249/MSS.0000000000003385

Turnbull C, Rahman N. Genetic predisposition to breast cancer: Past, present, and future. *Annu Rev Genomics Hum Genet*. 2008;9:321–45. doi: 10.1146/annurev.genom.9.081307.164339

Mavaddat N, Michailidou K, Dennis J, *et al.* Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genet*. 2019;104:21–34. doi: 10.1016/j.ajhg.2018.11.002

Yanes T, Young MA, Meiser B, *et al.* Clinical applications of polygenic breast cancer

risk: A critical review and perspectives of an emerging field. *Breast Cancer Research*.

2020;22. doi: 10.1186/s13058-020-01260-3

9 Michailidou K, Lindström S, Dennis J, *et al.* Association analysis identifies 65 new

breast cancer risk loci. *Nature*. 2017;551:92–4. doi: 10.1038/nature24284

10 Michailidou K, Beesley J, Lindstrom S, *et al.* Genome-wide association analysis of

more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.

Nat Genet. 2015;47:373–80. doi: 10.1038/ng.3242

11 Arthur RS, Wang T, Xue X, *et al.* Genetic factors, adherence to healthy lifestyle

behavior, and risk of invasive breast cancer among women in the UK biobank. *J Natl*

Cancer Inst. 2020;112:893–901. doi: 10.1093/jnci/djz241

12 Sudlow C, Gallacher J, Allen N, *et al.* UK Biobank: An Open Access Resource for

Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age.

PLoS Med. 2015;12. doi: 10.1371/journal.pmed.1001779

13 UK Biobank. UK Biobank Cardio Assessment Manual Version 1.0.

https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/Cardio.pdf.

14 Gonzales TI, Westgate K, Strain T, *et al.* Cardiorespiratory fitness assessment using

risk-stratified exercise testing and dose–response relationships with disease outcomes.

Sci Rep. 2021;11. doi: 10.1038/s41598-021-94768-3

15 Thompson DJ, Wells D, Selzam S, *et al.* A systematic evaluation of the performance

and properties of the UK Biobank Polygenic Risk Score (PRS) Release. *PLoS One*.

2024;19. doi: 10.1371/journal.pone.0307270

16 Wang L, Tang D. Immunosenescence promotes cancer development: from mechanisms

to treatment strategies. *Cell Communication and Signaling* . 2025;23. doi:

10.1186/s12964-025-02082-6

17 Bhardwaj P, Au CMC, Benito-Martin A, *et al.* Estrogens and breast cancer:

Mechanisms involved in obesity-related development, growth and progression. *Journal of Steroid Biochemistry and Molecular Biology*. 2019;189:161–70. doi: 10.1016/j.jsbmb.2019.03.002

Gladyshev VN, Kritchevsky SB, Clarke SG, *et al.* Molecular damage in aging. *Nat Aging*. 2021;1:1096–106. doi: 10.1038/s43587-021-00150-3

Myers J, Kokkinos P, Nyelin E. Physical activity, cardiorespiratory fitness, and the metabolic syndrome. *Nutrients*. 2019;11. doi: 10.3390/nu11071652

Kullo IJ, Khaleghi M, Hensrud DD. Markers of inflammation are inversely associated with V˙O 2 max in asymptomatic men. *J Appl Physiol*. 2007;102:1374–9. doi: 10.1152/japplphysiol.01028.2006

Lyu DW. Immunomodulatory effects of exercise in cancer prevention and adjuvant therapy: a narrative review. *Front Physiol*. 2023;14:1292580. doi: 10.3389/fphys.2023.1292580

Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444:860–7. doi: 10.1038/nature05485

Bulun SE, Chen D, Moy I, *et al.* Aromatase, breast cancer and obesity: A complex interaction. *Trends in Endocrinology and Metabolism*. 2012;23:83–9. doi: 10.1016/j.tem.2011.10.003

Colditz GA, Bohlke K, Berkey CS. Breast cancer risk accumulation starts early: Prevention must also. *Breast Cancer Res Treat*. 2014;145:567–79. doi: 10.1007/s10549-014-2993-8

Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? *Breast Cancer Res Treat*. 2002;72:107–15. doi: 10.1023/a:1014891216621

Figure Legends

Figure 1. Flow diagram of participant selection from the UK Biobank. The final analytic

sample comprised 13,907 postmenopausal women with available CRF and PRS.

Figure 2. Nelson–Aalen cumulative hazard curves for incident breast cancer according to (A)

PRS quartiles, (B) CRF quartiles, and (C) joint categories of PRS and CRF.

Figure 3. Joint associations and interaction of CRF and PRS with breast cancer incidence.

The models were adjusted for family history of breast cancer, Townsend deprivation index,

alcohol consumption frequency, smoking status, hormone replacement therapy use, age at

menarche, number of live births, age at first birth, and body fat percentage.

Table 1. Characteristics of participants at baseline according to CRF quartiles

	Total	CRF quartiles			
		Q1	Q2	Q3	Q4
n	13907	3530	3473	3436	3468
Age at baseline (years)	61.0 (56.0–64.0)	61.0 (57.0–65.0)	61.0 (56.0–64.0)	61.0 (56.0–64.0)	61.0 (56.0–63.0)
Height (cm)	163.0 (159.0–167.0)	162.5 (158.0–166.0)	163.0 (159.0–167.0)	163.0 (159.0–167.0)	163.0 (159.0–167.0)
Body mass (kg)	68.6 (61.6–77.3)	79.0 (70.4–89.3)	71.2 (64.9–78.6)	66.7 (61.2–72.5)	61.3 (56.5–66.7)
BMI (kg/m^2)	25.9 (23.4–29.1)	30.0 (26.8–33.8)	26.9 (24.7–29.6)	25.1 (23.3–27.3)	23.2 (21.5–25.0)
Body fat percentage (%)	36.8 (32.3–41.3)	42.1 (38.1–45.7)	38.4 (34.7–41.7)	35.5 (32.2–38.8)	31.8 (28.2–35.4)
Estimated VO$_2$max (mL·kg^{-1}·min^{-1})	24.5 (21.5–27.8)	19.5 (17.6–20.7)	23.1 (22.3–23.9)	25.9 (24.9–26.9)	30.4 (28.7–32.6)
Breast cancer PRS	−0.18 (−0.84–0.51)	−0.18 (−0.84–0.50)	−0.18 (−0.83–0.52)	−0.16 (−0.84–0.54)	−0.19 (−0.85–0.47)
Family history of breast cancer	1571 (11.4)	427 (12.2)	372 (10.8)	384 (11.3)	388 (11.3)
Townsend deprivation index	−2.23 (−3.62–0.02)	−2.11 (−3.55–0.21)	−2.20 (−3.58––0.12)	−2.28 (−3.63––0.12)	−2.31 (−3.71–0.05)
Alcohol consumption frequency					
<3 times a month	4595 (33.1)	1500 (42.5)	1209 (34.8)	1006 (29.3)	880 (25.4)
1–4 times a week	6598 (47.5)	1553 (44.0)	1629 (46.9)	1694 (49.4)	1722 (49.7)
Daily or almost daily	2706 (19.5)	476 (13.5)	633 (18.2)	732 (21.3)	865 (24.9)
Smoking status					
Never	8255 (59.5)	2139 (60.9)	2131 (61.4)	1988 (58.1)	1997 (57.7)
Former	4679 (33.7)	1151 (32.7)	1110 (32.0)	1197 (35.0)	1221 (35.3)
Current	934 (6.7)	225 (6.4)	227 (6.5)	238 (7.0)	244 (7.0)
Ever use of hormone replacement therapy	6403 (46.1)	1595 (45.3)	1650 (47.6)	1645 (48.0)	1513 (43.7)
Age at menarche					
<12	2778 (20.6)	881 (25.7)	708 (20.9)	611 (18.3)	578 (17.3)

12–13	6008 (44.5)	1475 (43.1)	1510 (44.5)	1516 (45.4)	1507 (45.0)
≥14	4720 (34.9)	1068 (31.2)	1174 (34.6)	1214 (36.3)	1264 (37.7)
Number of live births					
0	2637 (19.0)	660 (18.7)	630 (18.1)	647 (18.8)	700 (20.2)
1	1698 (12.2)	406 (11.5)	443 (12.8)	459 (13.4)	390 (11.3)
2	6462 (46.5)	1663 (47.2)	1618 (46.6)	1587 (46.2)	1594 (46.0)
≥3	3101 (22.3)	797 (22.6)	781 (22.5)	742 (21.6)	781 (22.5)
Age at first birth					
Nulliparous	2637 (19.0)	660 (18.7)	630 (18.2)	647 (18.8)	700 (20.2)
<25	4120 (29.7)	1256 (35.6)	1082 (31.2)	965 (28.1)	817 (23.6)
25–29	4478 (32.2)	1063 (30.2)	1137 (32.8)	1125 (32.8)	1153 (33.3)
≥30	2656 (19.1)	546 (15.5)	620 (17.9)	696 (20.3)	794 (22.9)
Age at menopause					
<45	927 (6.7)	270 (7.6)	235 (6.8)	203 (5.9)	219 (6.3)
45–49	2648 (19.0)	610 (17.3)	674 (19.4)	704 (20.5)	660 (19.0)
50–54	6298 (45.3)	1580 (44.8)	1499 (43.2)	1561 (45.4)	1658 (47.8)
≥55	2229 (16.0)	548 (15.5)	573 (16.5)	581 (16.9)	527 (15.2)
Unknown	1805 (13.0)	522 (14.8)	492 (14.2)	387 (11.3)	404 (11.6)

Data are presented as median (interquartile range) for continuous variables and count (percent) for categorical variables.
Denominators may vary due to missing data.
BMI, body mass index; CRF, cardiorespiratory fitness; PRS, polygenic risk score; VO$_2$max, maximal oxygen uptake

Table 2. Association between CRF and incident breast cancer according to PRS quartiles

PRS	CRF	n	Events	Incidence rate (per 1000 PY)	Crude HR (95% CI)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
	Q1	3530	137	3.8	1.00 (ref)	1.00 (ref)	1.00 (ref)
	Q2	3473	137	3.8	1.01 (0.80–1.29)	1.00 (0.79–1.27)	1.02 (0.80–1.31)
Overall	Q3	3436	130	3.6	0.97 (0.76–1.23)	0.94 (0.74–1.20)	0.98 (0.75–1.28)
	Q4	3468	96	2.7	0.71 (0.55–0.92)	0.69 (0.53–0.90)	0.73 (0.54–1.00)
	p for trend				0.003	0.001	0.013
	Q1	876	13	1.4	1.00 (ref)	1.00 (ref)	1.00 (ref)
	Q2	859	15	1.7	1.17 (0.54–2.50)	1.18 (0.54–2.58)	1.10 (0.49–2.44)
Q1	Q3	860	16	1.8	1.24 (0.58–2.63)	1.26 (0.58–2.72)	1.10 (0.48–2.51)
	Q4	882	9	1.0	0.67 (0.28–1.59)	0.61 (0.25–1.51)	0.48 (0.17–1.37)
	p for trend				0.62	0.419	0.282
	Q1	895	18	1.9	1.00 (ref)	1.00 (ref)	1.00 (ref)
	Q2	875	22	2.4	1.25 (0.66–2.36)	1.25 (0.66–2.37)	1.32 (0.68–2.54)
Q2	Q3	836	23	2.6	1.34 (0.72–2.52)	1.30 (0.69–2.47)	1.45 (0.72–2.91)
	Q4	871	17	1.9	0.96 (0.49–1.89)	0.95 (0.47–1.90)	1.12 (0.49–2.54)
	p for trend				0.972	0.986	0.634
	Q1	882	43	4.8	1.00 (ref)	1.00 (ref)	1.00 (ref)
	Q2	857	33	3.7	0.77 (0.49–1.22)	0.75 (0.48–1.20)	0.85 (0.53–1.38)
Q3	Q3	848	33	3.7	0.80 (0.50–1.26)	0.76 (0.48–1.21)	0.93 (0.56–1.54)
	Q4	889	34	3.7	0.78 (0.50–1.23)	0.76 (0.48–1.20)	1.05 (0.60–1.85)
	p for trend				0.112	0.113	0.733
	Q1	877	63	7.0	1.00 (ref)	1.00 (ref)	1.00 (ref)
	Q2	882	67	7.5	1.07 (0.76–1.51)	1.03 (0.73–1.46)	1.01 (0.71–1.44)
Q4	Q3	892	58	6.3	0.90 (0.63–1.29)	0.87 (0.60–1.24)	0.84 (0.57–1.24)
	Q4	826	36	4.2	0.61 (0.40–0.92)	0.57 (0.38–0.87)	0.54 (0.33–0.87)
	p for trend				0.002	0.001	0.001

Model 1 was adjusted for family history of breast cancer, Townsend deprivation index, alcohol consumption frequency, smoking status, hormone replacement therapy use, age at menarche, number of live births, and age at first birth. Model 2 was additionally adjusted for body fat percentage.
CI, confidence interval; CRF, cardiorespiratory fitness; HR, hazard ratio; PRS, polygenic risk score; PY, person-years; Ref, reference

```
┌─────────────────────────────────────┐
│  UK Biobank participants recruited   │
│            N=502,128                 │
└─────────────────────────────────────┘
                  │
                  ▼
┌─────────────────────────────────────┐
│              Excluded                │
│                                      │
│  • Men (n=228,973)                   │
│  • Missing VO₂max (n=238,082)        │
│  • Premenopausal (n=12,198)          │
│  • Hysterectomy (n=2,184)            │
│  • Prior cancer (n=2,294)            │
│  • Non-European ancestry (n=4,297)   │
│  • Missing PRS (n=58)                │
│  • Extreme VO₂max (n=135)            │
└─────────────────────────────────────┘
                  │
                  ▼
┌─────────────────────────────────────┐
│         Final analytic sample        │
│      Postmenopausal women with       │
│          CRF and PRS data            │
│             N=13,907                 │
└─────────────────────────────────────┘
```

UK Biobank participants recruited
N=502,128

Excluded

- Men (n=228,973)
- Missing VO_2max (n=238,082)
- Premenopausal (n=12,198)
- Hysterectomy (n=2,184)
- Prior cancer (n=2,294)
- Non-European ancestry (n=4,297)
- Missing PRS (n=58)
- Extreme VO_2max (n=135)

Final analytic sample
Postmenopausal women with
CRF and PRS data
N=13,907

PRS	CRF		n	Events	Incidence rate (per 1000 PY)	HR (95% CI)	p
Overall							
Q1–Q3	Q1–Q3		7789	216	2.7	1.00 (ref)	
Q1–Q3	Q4		2642	60	2.2	0.85 (0.62–1.15)	0.286
Q4	Q1–Q3		2650	188	7.0	2.58 (2.12–3.14)	<0.001
Q4	Q4		826	36	4.2	1.58 (1.10–2.29)	0.014
Age 40–59 years							
Q1–Q3	Q1–Q3		3252	73	2.1	1.00 (ref)	
Q1–Q3	Q4		1096	24	2.1	1.06 (0.64–1.76)	0.808
Q4	Q1–Q3		1070	59	5.3	2.43 (1.72–3.43)	<0.001
Q4	Q4		336	16	4.6	2.31 (1.30–4.10)	0.004
Age ≥60 years							
Q1–Q3	Q1–Q3		4537	143	3.0	1.00 (ref)	
Q1–Q3	Q4		1546	36	2.2	0.73 (0.50–1.05)	0.085
Q4	Q1–Q3		1580	129	8.1	2.66 (2.10–3.38)	<0.001
Q4	Q4		490	20	4.0	1.29 (0.81–2.06)	0.285
BMI <25 kg/m²							
Q1–Q3	Q1–Q3		2346	51	2.1	1.00 (ref)	
Q1–Q3	Q4		2002	46	2.2	1.10 (0.73–1.66)	0.647
Q4	Q1–Q3		784	53	6.6	3.16 (2.14–4.64)	<0.001
Q4	Q4		613	30	4.7	2.28 (1.44–3.63)	<0.001
BMI ≥25 kg/m²							
Q1–Q3	Q1–Q3		5442	165	2.9	1.00 (ref)	
Q1–Q3	Q4		640	14	2.1	0.69 (0.39–1.19)	0.182
Q4	Q1–Q3		1866	135	7.1	2.40 (1.91–3.01)	<0.001
Q4	Q4		212	6	2.7	0.85 (0.38–1.94)	0.707

0.25 0.5 1 2 4 8

HR (95% CI)